Use of a Food and Drug Administration-Approved Type 1 Diabetes Mellitus Simulator to Evaluate and Optimize a Proportional-Integral-Derivative Controller.

摘要

Background Clinical studies have shown that the Medtronic proportional-integral-derivative (PID) control with insulin feedback (IFB) provides stable 24 h glucose control, but with high postprandial glucose. We coupled this algorithm to a Food and Drug Administration-approved type 1 diabetes mellitus simulator to determine whether a proportional-derivative controller with preprogrammed basal rates (PDBASAL) would have better performance. Methods We performed simulation studies on 10 adult subjects to (1) obtain the basal profiles for the PDBASAL controller (2) define the pharmacokinetic/pharmacodynamic profile used to effect IFB, (3) optimize the PID and PDBASAL control parameters, (4) evaluate improvements obtained with IFB, and (5) develop a method to simulate changes in insulin sensitivity and assess the ability of each algorithm to respond to such changes.